iShares Biotechnology ETF
463 hedge funds and large institutions have $4.63B invested in iShares Biotechnology ETF in 2016 Q3 according to their latest regulatory filings, with 87 funds opening new positions, 146 increasing their positions, 137 reducing their positions, and 44 closing their positions.
98% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 44
25% more funds holding in top 10
Funds holding in top 10: 20 → 25 (+5)
24% more capital invested
Capital invested by funds: $3.72B → $4.63B (+$905M)
8% more funds holding
Funds holding: 428 → 463 (+35)
7% more repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 137
47% less call options, than puts
Call options by funds: $650M | Put options by funds: $1.24B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$310M |
| 2 |
Morgan Stanley
New York
|
+$138M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$85.9M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$65.4M |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$51.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$127M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$115M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$57M |
| 4 |
Two Sigma Advisers
New York
|
-$41.5M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$26.8M |
IBB Hedge Fund Activity: Q3 2016 in Review
463 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2016, worth a combined $4.63B — up 24% from $3.72B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new IBB positions and 44 closed out — a net gain of 43 holders — while 146 added to existing stakes and 137 trimmed.
The largest buyer was Citigroup, adding an estimated $310M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $127M.
- 463 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2016, up from 428 in Q2 2016.
- Funds reported $4.63B of iShares Biotechnology ETF stock for Q3 2016, up 24% quarter-over-quarter.
- 87 funds opened new iShares Biotechnology ETF positions in Q3 2016 and 44 closed out, a net change of +43 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2016 was Citigroup, an estimated $310M added.
- The largest iShares Biotechnology ETF seller in Q3 2016 was BNP Paribas Financial Markets, an estimated $127M sold.
Based on aggregated 13F filings for Q3 2016.